Trial Profile
Randomised Phase 2 Study of Nivolumab Versus Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2022 Status changed from active, no longer recruiting to discontinued.
- 27 Apr 2021 Planned End Date changed from 1 Jun 2020 to 1 Dec 2021.
- 27 Apr 2021 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.